TABLE OF CONTENTS
1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 35
1.3 OVERVIEW OF THE EUROPE TUMOR ABLATION MARKET 35
1.4 CURRENCY AND PRICING 37
1.5 LIMITATIONS 37
1.6 MARKETS COVERED 37
2 MARKET SEGMENTATION 40
2.1 MARKETS COVERED 40
2.2 GEOGRAPHICAL SCOPE 41
2.3 YEARS CONSIDERED FOR THE STUDY 42
2.4 DBMR TRIPOD DATA VALIDATION MODEL 43
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 46
2.6 MULTIVARIATE MODELLING 47
2.7 TYPE SEGMENT LIFELINE CURVE 48
2.8 MARKET END USERS COVERAGE GRID 49
2.9 DBMR MARKET POSITION GRID 50
2.10 VENDOR SHARE ANALYSIS 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHTS 55
4.1 PESTEL ANALYSIS 56
4.2 PORTER'S FIVE FORCES MODEL 57
5 REGULATORY FRAMEWORK 58
5.1 REGULATORY SCENARIO IN GERMANY 58
6 MARKET OVERVIEW 59
6.1 DRIVERS 61
6.1.1 RISING PREVALENCE OF CANCER EUROPELY 61
6.1.2 INCREASING INCLINATION OF SURGEONS AND PATIENTS TOWARD MINIMALLY INVASIVE PROCEDURES 61
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 62
6.1.4 INCREASING AWARENESS AND EDUCATION 62
6.2 RESTRAINTS 63
6.2.1 REGULATORY HURDLES FOR APPROVAL 63
6.2.2 LIMITED CLINICAL EVIDENCE 63
6.3 OPPORTUNITIES 64
6.3.1 FAVORABLE REIMBURSEMENT SCENARIO 64
6.3.2 STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64
6.4 CHALLENGES 65
6.4.1 TECHNICAL CHALLENGES IN TARGETING THE TUMOR 65
6.4.2 COMPETITION FROM ALTERNATIVE TREATMENT MODALITIES 65
7 EUROPE TUMOR ABLATION MARKET, BY TYPE 66
7.1 OVERVIEW 67
7.2 THERMAL ABLATION 70
7.2.1 TUMOR ABLATION SYSTEMS 71
7.2.1.1 RADIOFREQUENCY 72
7.2.1.1.1 BIPOLAR 72
7.2.1.1.2 MULTIPOLAR 72
7.2.2 IMAGE GUIDANCE PRODUCTS AND ACCESSORIES 72
7.2.2.1 CT 73
7.2.2.2 MR IMAGING 73
7.2.2.3 FLUOROSCOPY 73
7.2.2.4 OTHERS 73
7.2.2.5 MICROWAVE 73
7.2.2.6 CRYOABLATION 73
7.2.2.7 HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) 73
7.2.2.8 LASER 73
7.3 CHEMICAL ABLATION 73
7.3.1 ETHANOL 74
7.3.2 ACETIC ACID 74
8 EUROPE TUMOR ABLATION MARKET, BY TYPES OF TREATMENT 75
8.1 OVERVIEW 76
8.2 PERCUTANEOUS 79
8.2.1 BREAST CANCER 80
8.2.2 LUNG CANCER 80
8.2.3 PROSTATE CANCER 80
8.2.4 LIVER CANCER 80
8.2.5 KIDNEY CANCER 80
8.2.6 OTHER CANCERS 80
8.3 LAPAROSCOPY 80
8.3.1 BREAST CANCER 81
8.3.2 LUNG CANCER 81
8.3.3 PROSTATE CANCER 81
8.3.4 LIVER CANCER 81
8.3.5 KIDNEY CANCER 82
8.3.6 OTHER CANCERS 82
8.4 SURGICAL 82
8.4.1 BREAST CANCER 83
8.4.2 LUNG CANCER 83
8.4.3 PROSTATE CANCER 83
8.4.4 LIVER CANCER 83
8.4.5 KIDNEY CANCER 83
8.4.6 OTHER CANCERS 83
9 EUROPE TUMOR ABLATION MARKET, BY CANCER TYPE 84
9.1 OVERVIEW 85
9.2 BREAST CANCER 88
9.3 LUNG CANCER 88
9.4 PROSTATE CANCER 89
9.5 LIVER CANCER 90
9.6 KIDNEY CANCER 91
9.7 BONE CANCER 92
9.8 OTHERS 93
10 EUROPE TUMOR ABLATION MARKET, BY END USERS 94
10.1 OVERVIEW 95
10.2 HOSPITALS 98
10.3 ONCOLOGY CENTERS 98
10.4 OTHERS 99
11 EUROPE TUMOR ABLATION MARKET, BY DISTRIBUTION CHANNEL 100
11.1 OVERVIEW 101
11.2 DIRECT TENDER 104
11.3 RETAIL SALES 104
12 EUROPE TUMOR ABLATION MARKET, BY REGION 106
12.1 EUROPE 107
12.1.1 GERMANY 117
12.1.2 U.K. 122
12.1.3 FRANCE 127
12.1.4 ITALY 132
12.1.5 RUSSIA 137
12.1.6 SPAIN 142
12.1.7 NETHERLANDS 147
12.1.8 SWITZERLAND 152
12.1.9 BELGIUM 157
12.1.10 TURKEY 162
12.1.11 REST OF EUROPE 167
13 EUROPE TUMOR ABLATION MARKET, COMPANY LANDSCAPE 168
13.1 COMPANY SHARE ANALYSIS: EUROPE 168
14 SWOT ANALYSIS 169
15 COMPANY PROFILE 170
15.1 BOSTON SCIENTIFIC CORPORATION 170
15.1.1 COMPANY SNAPSHOT 170
15.1.2 REVENUE ANALYSIS 170
15.1.3 COMPANY SHARE ANALYSIS 171
15.1.4 PRODUCT PORTFOLIO 171
15.1.5 RECENT DEVELOPMENT 171
15.2 MEDTRONIC 172
15.2.1 COMPANY SNAPSHOT 172
15.2.2 REVENUE ANALYSIS 172
15.2.3 COMPANY SHARE ANALYSIS 173
15.2.4 PRODUCT PORTFOLIO 173
15.2.5 RECENT DEVELOPMENT 173
15.3 OLYMPUS 174
15.3.1 COMPANY SNAPSHOT 174
15.3.2 REVENUE ANALYSIS 174
15.3.3 COMPANY SHARE ANALYSIS 175
15.3.4 PRODUCT PORTFOLIO 175
15.3.5 RECENT DEVELOPMENT 175
15.4 STRYKER 176
15.4.1 COMPANY SNAPSHOT 176
15.4.2 REVENUE ANALYSIS 176
15.4.3 COMPANY SHARE ANALYSIS 177
15.4.4 PRODUCT PORTFOLIO 177
15.4.5 RECENT DEVELOPMENT 177
15.5 BIOTRONIK 178
15.5.1 COMPANY SNAPSHOT 178
15.5.2 COMPANY SHARE ANALYSIS 178
15.5.3 PRODUCT PORTFOLIO 179
15.5.4 RECENT DEVELOPMENT 179
15.6 ANGIODYNAMICS. 180
15.6.1 COMPANY SNAPSHOT 180
15.6.2 REVENUE ANALYSIS 180
15.6.3 PRODUCT PORTFOLIO 181
15.6.4 RECENT DEVELOPMENT 181
15.7 BIOVENTUS LLC. 182
15.7.1 COMPANY SNAPSHOT 182
15.7.2 PRODUCT PORTFOLIO 182
15.7.3 RECENT DEVELOPMENT 182
15.8 BVM MEDICAL LIMITED 183
15.8.1 COMPANY SNAPSHOT 183
15.8.2 PRODUCT PORTFOLIO 183
15.8.3 RECENT DEVELOPMENT 183
15.9 EDAP TMS 184
15.9.1 COMPANY SNAPSHOT 184
15.9.2 REVENUE ANALYSIS 184
15.9.3 PRODUCT PORTFOLIO 185
15.9.4 RECENT DEVELOPMENT 185
15.10 ETHICON, INC. 186
15.10.1 COMPANY SNAPSHOT 186
15.10.2 PRODUCT PORTFOLIO 186
15.10.3 RECENT DEVELOPMENT 186
15.11 HEALTHTRONICS, INC. 187
15.11.1 COMPANY SNAPSHOT 187
15.11.2 PRODUCT PORTFOLIO 187
15.11.3 RECENT DEVELOPMENT 187
15.12 ICECURE MEDICAL 188
15.12.1 COMPANY SNAPSHOT 188
15.12.2 REVENUE ANALYSIS 188
15.12.3 PRODUCT PORTFOLIO 189
15.12.4 RECENT DEVELOPMENT 189
15.13 INSIGHTEC. 190
15.13.1 COMPANY SNAPSHOT 190
15.13.2 PRODUCT PORTFOLIO 190
15.13.3 RECENT DEVELOPMENT 190
15.14 INTEGRA LIFESCIENCES 191
15.14.1 COMPANY SNAPSHOT 191
15.14.2 REVENUE ANALYSIS 191
15.14.3 PRODUCT PORTFOLIO 192
15.14.4 RECENT DEVELOPMENT 192
15.15 MERIT MEDICAL SYSTEMS. 193
15.15.1 COMPANY SNAPSHOT 193
15.15.2 REVENUE ANALYSIS 193
15.15.3 PRODUCT PORTFOLIO 194
15.15.4 RECENT DEVELOPMENT 194
15.16 SONABLATE CORP. 195
15.16.1 COMPANY SNAPSHOT 195
15.16.2 PRODUCT PORTFOLIO 195
15.16.3 RECENT DEVELOPMENT 195
15.17 TERUMO EUROPE NV 196
15.17.1 COMPANY SNAPSHOT 196
15.17.2 PRODUCT PORTFOLIO 196
15.17.3 RECENT DEVELOPMENT 196
16 QUESTIONNAIRE 197
17 RELATED REPORTS 200

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.